[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f3OJkjgG4VZJ-jsQqE88oIqtFa9c-EIr64hH3BkGvR50":8,"$fAVHoshTvwu5LBFmuofXZfG3a6yaNHfs6XEEcD-oL2Gc":55,"$f2LeI0osBiNTd1NTlG_uwtiW4HC_CgaNkTYHloIl7b8A":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},51459,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"靶向药物与安全用药全解析：HER2阳性乳腺癌治疗方案实用指南","","https://cdn.yishi-tong.com/console/store-unknown/zNfNz_cyOgRRc_32Xy1Upvz1wWH1T2a7.png","\u003Cdiv class=\"her2-guide-container\">\n \u003Ch2 id=\"material_title\" class=\"her2-guide-main-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">靶向药物与安全用药全解析：HER2阳性乳腺癌治疗方案实用指南\u003C/h2>\n \n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 药品类别与核心用途概览 🧬\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cp>\n 说起来，HER2阳性乳腺癌相关药物其实主要分为三大类：靶向单克隆抗体（如曲妥珠单抗、帕妥珠单抗）、小分子酪氨酸激酶抑制剂（如拉帕替尼、吡咯替尼）、抗体药物偶联物（如恩美曲妥珠单抗、德喜曲妥珠单抗）。这些药物被广泛应用于\u003Cem>HER2阳性乳腺癌的联合化疗、辅助治疗与维持治疗\u003C/em>。本文将帮你抓住7个重要用药细节，确保你用得明白、用得放心。 \n \u003C/p>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 抗HER2药物的作用机制一览 🌟\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>单克隆抗体\u003C/b>（如曲妥珠单抗、帕妥珠单抗）：主要通过与HER2受体结合，阻断信号传导，减少肿瘤细胞的生长与分裂，并激活身体免疫系统针对异常细胞发挥作用。\n \u003C/li>\n \u003Cli>\n \u003Cb>小分子酪氨酸激酶抑制剂\u003C/b>（如拉帕替尼、吡咯替尼）：通过抑制HER2相关酪氨酸激酶活性，干扰肿瘤细胞内部信号通路。\n \u003C/li>\n \u003Cli>\n \u003Cb>抗体药物偶联物（ADC）\u003C/b>（如恩美曲妥珠单抗T-DM1、德喜曲妥珠单抗T-DXd）：抗体部分识别并结合HER2受体，将高效化疗药物定向递送进入肿瘤细胞，务求“精准打击，减少误伤”。\n \u003C/li>\n \u003C/ul>\n \u003Cp>\n 需要注意，各类药物的具体作用环节不同，联合用药时常能互补增强效果，有效延缓耐药发生（Swain, S.M. et al., 2015, \u003Ci>NEJM\u003C/i>）。\n \u003C/p>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 正确的用法用量详解 🕑\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>单克隆抗体类（曲妥珠单抗、帕妥珠单抗等）：\u003C/b>\u003Cbr>\n 这类药物通常通过静脉输注方式给予。首次输注时间较长（可能超过90分钟），后续缩短至30分钟左右。剂量严格与体重、药品说明书一致。治疗初期配合化疗使用，进入维持阶段可单独使用。\n \u003C/li>\n \u003Cli>\n \u003Cb>小分子酪氨酸激酶抑制剂（拉帕替尼、吡咯替尼等）：\u003C/b>\u003Cbr>\n 口服制剂。常规建议每日一次，需整片吞服，不可掰开、嚼碎。部分药物需随餐服用，有些相反，务必遵医嘱。\n \u003Cdiv class=\"her2-guide-tip\">正确做法：服药方式按说明书或医生指示，不随意更改用药时间或剂量。\u003C/div>\n \u003C/li>\n \u003Cli>\n \u003Cb>抗体药物偶联物（T-DM1、T-DXd）：\u003C/b>\u003Cbr>\n 静脉给药，按照体重和周期正规滴注。用药间隔一般为每3周一次，用药期间严密监测血象和肝功能。\n \u003C/li>\n \u003C/ul>\n \u003Cp>\n 有用药案例显示，一位48岁女性患者按照个体化剂量，接受曲妥珠单抗联合紫杉类化疗，期间剂量调整有效减轻了骨髓抑制带来的困扰。\n \u003C/p>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 常见剂型及服用小技巧 💊\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>注射剂：\u003C/b>单克隆抗体及大部分ADC类药物采用静脉滴注。首剂时需密切监测过敏反应，有经验的医护人员操作，在正规医疗环境施用。\n \u003C/li>\n \u003Cli>\n \u003Cb>片剂/胶囊：\u003C/b>如吡咯替尼、拉帕替尼。大多建议用温水送服，不可掰开或嚼碎，以保证药效。部分药品随餐服用可减轻胃部不适。\n \u003C/li>\n \u003Cli>\n \u003Cb>服药间隔：\u003C/b>自行加餐或漏服时，切勿随意双倍补服，遵循说明书指示即可。\n \u003C/li>\n \u003C/ul>\n \u003Cp>\n 正确做法：服药前后半小时内，避免饮用葡萄柚汁等可能影响药效的饮品。\n \u003C/p>\n \u003Cdiv class=\"her2-guide-tip\">特别提醒：部分剂型需要低温保存，开封后应限时用完。\u003C/div>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 药物相互作用不可忽视！⚠️\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cp>\n HER2靶向药物与其它药品（如部分抗生素、抗凝药、质子泵抑制剂等）可能存在相互作用。以下几点尤需关注：\n \u003C/p>\n \u003Cul>\n \u003Cli>\n 部分抗生素（如红霉素）与拉帕替尼同服，会干扰其代谢，增加不良反应风险。\n \u003C/li>\n \u003Cli>\n 拉帕替尼、吡咯替尼、来那替尼等药物与质子泵抑制剂（PPI）合用，可降低血药浓度，影响疗效。\n \u003C/li>\n \u003Cli>\n 某些抗凝药如华法林与ADC类药物同用，监测凝血功能是必须的。\n \u003C/li>\n \u003Cli>\n 葡萄柚或其汁液会影响部分小分子药物在肝脏代谢，从而加强或降低药效。\n \u003C/li>\n \u003C/ul>\n \u003Cdiv class=\"her2-guide-tip\">正确做法：用药期间如需加用其它药品，建议主动咨询医生或药师，避免自作主张换药。\u003C/div>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 特殊人群用药指导 👩‍🔬👴\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>老年患者：\u003C/b>往往代谢减慢，建议根据肝、肾功能个体调整剂量。例如，拉帕替尼在肝损害时需降低用量，有研究显示老年患者副作用风险略高（Blumenthal, G.M. et al., 2017, \u003Ci>Oncologist\u003C/i>）。\n \u003C/li>\n \u003Cli>\n \u003Cb>育龄及妊娠期女性：\u003C/b>绝大部分抗HER2药物在妊娠及哺乳期属禁用或慎用。务必咨询医生，严禁自行决定。\n \u003C/li>\n \u003Cli>\n \u003Cb>肝肾功能异常：\u003C/b>药物如吡咯替尼、拉帕替尼需要定期肝/肾功能监测，调整用量。\n \u003C/li>\n \u003Cli>\n \u003Cb>儿童：\u003C/b>目前无充分证据推荐用于未成年患者。\n \u003C/li>\n \u003C/ul>\n \u003Cp>正确做法：每次复诊务必告知医生全部用药及身体状况变化，尤其是肝肾功能、怀孕打算等。\u003C/p>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 常见不良反应与应对办法 😷\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>骨髓抑制：\u003C/b>常见于联合化疗期间，包括贫血、白细胞低下等。需要定期抽血监测。有患者在维持性化疗联合曲妥珠单抗期间，出现轻中度贫血，经调整化疗剂量控制反应。\n \u003C/li>\n \u003Cli>\n \u003Cb>心脏毒性：\u003C/b>曲妥珠单抗等单抗药物有引起心功能减弱的风险，定期心电图及心超检查属于常规操作。\n \u003C/li>\n \u003Cli>\n \u003Cb>肝功能损害：\u003C/b>小分子口服药（如拉帕替尼）可能影响肝酶水平，定期检测必要。\n \u003C/li>\n \u003Cli>\n \u003Cb>胃肠道反应：\u003C/b>包括恶心、腹泻、食欲不振等。调整饮食、多饮水、轻度症状可暂时减量或短暂停药，严重时必须立即就医。\n \u003C/li>\n \u003Cli>\n \u003Cb>其他常见问题：\u003C/b>如皮疹、手足综合征等，高发于小分子口服药物，轻度者可对症处理，明显不适即停药就诊。\n \u003C/li>\n \u003C/ul>\n \u003Cdiv class=\"her2-guide-tip\">出现不良反应时切勿自行停药或乱加药，应尽快联络医生，协商最合适的处理方案。\u003C/div>\n \u003Cp style=\"margin-top:8px;\">\n 临床数据显示，T-DM1导致3-4级不良反应发生率约为25%，明显重于常规化疗（Verma, S. et al., 2012, \u003Ci>NEJM\u003C/i>）。\n \u003C/p>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 储存条件及药品管理 📦\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>冷链储存：\u003C/b>大部分单克隆抗体及ADC类药物均需2-8°C冷藏，避免冷冻及阳光直射。开封后若未使用，按说明丢弃。\n \u003C/li>\n \u003Cli>\n \u003Cb>口服药品：\u003C/b>密闭、干燥处保存，避免潮湿，远离儿童。\n \u003C/li>\n \u003Cli>\n \u003Cb>有效期：\u003C/b>每次用药需检查外包装批号和过期时间，勿用过期药。\n \u003C/li>\n \u003Cli>\n \u003Cb>废弃处理：\u003C/b>剩余药品和包装按说明远离生活垃圾处理，一般送回专业药房或医疗机构销毁。\n \u003C/li>\n \u003C/ul>\n \u003Cdiv class=\"her2-guide-tip\">正确做法：定期清点家庭药品，存放于安全、上锁的柜子里。\u003C/div>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09. 遇到漏服或者用药过量怎么办？ 🤔\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n \u003Cb>口服药物漏服：\u003C/b>如记起时距下次服药超4小时，可补服一次。如临近下次服药，直接跳过，不可双倍补服。\n \u003C/li>\n \u003Cli>\n \u003Cb>注射用药漏用：\u003C/b>及时联系医院，不要自行补打。让专业医务人员安排后续方案。\n \u003C/li>\n \u003Cli>\n \u003Cb>用药过量：\u003C/b>一旦出现明显不适（异常心跳、昏迷、严重过敏等），应立即停药并就医。\n \u003C/li>\n \u003C/ul>\n \u003Cdiv class=\"her2-guide-tip\">特别提醒：长期遗漏或频繁多服都可能增加副作用风险，严禁自行调整方案。\u003C/div>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10. 总结：安全用药的关键提醒 ✔️\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Cul>\n \u003Cli>\n HER2相关药物属于特殊管理品种。专业指导、定期复诊和监测是用药安全的“保险绳”。\n \u003C/li>\n \u003Cli>\n 切记严格按照说明书和医嘱使用。任何剂量、周期、联合用药的调整请务必由医生决定，切莫“参考他人经验”。\n \u003C/li>\n \u003C/ul>\n \u003Cp>\n 控制心脏毒性与骨髓抑制等问题是全程治疗不可忽视的环节。遇到任何困惑可随时咨询专业药师或医生支持。用对药，是每个人健康道路上的关键一步。\n \u003C/p>\n \u003C/div>\n \u003C/div>\n\n \u003Cdiv class=\"her2-guide-section\">\n \u003Cdiv class=\"her2-guide-section-bg\">\n \u003Ch2 class=\"her2-guide-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📚 参考文献（References）\u003C/h2>\n \u003C/div>\n \u003Cdiv class=\"her2-guide-section-content\">\n \u003Col class=\"her2-guide-reference-list\">\n \u003Cli>\n Swain, S. M., Baselga, J., Kim, S. B., et al. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 372(8), 724-734. https://doi.org/10.1056/NEJMoa1413513\n \u003C/li>\n \u003Cli>\n Verma, S., Miles, D., Gianni, L., et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 367(19), 1783-1791. https://doi.org/10.1056/NEJMoa1209124\n \u003C/li>\n \u003Cli>\n Blumenthal, G. M., Cortazar, P., Zhang, J. J., et al. (2017). FDA Approval Summary: Pertuzumab for Neoadjuvant Treatment of Breast Cancer. \u003Ci>The Oncologist\u003C/i>, 22(7), 853-859. https://doi.org/10.1634/theoncologist.2017-0090\n \u003C/li>\n \u003C/ol>\n \u003C/div>\n \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.her2-guide-container {\n background-color: #faf9f4;\n padding: 32px 0 54px 0;\n font-family: 'PingFang SC', 'Helvetica Neue', Arial, 'Microsoft YaHei', sans-serif;\n color: #24292f;\n max-width: 860px;\n margin: 0 auto;\n border-radius: 20px;\n box-shadow: 0 8px 36px rgba(150, 150, 160, 0.08);\n}\n.her2-guide-main-title {\n text-align: center;\n font-size: 2.6em;\n font-weight: 700;\n letter-spacing: 2px;\n color: #26456d;\n margin: 0 0 38px 0;\n padding-top: 12px;\n}\n.her2-guide-section {\n margin-bottom: 38px;\n border-radius: 14px;\n overflow: hidden;\n box-shadow: 0 2px 12px rgba(50, 100, 140, 0.03), 0 0.5px 1px rgba(0,0,0,0.03);\n}\n.her2-guide-section-bg {\n background: linear-gradient(90deg, #f3fafd 0%, #f5f5fa 67%);\n min-height: 60px;\n display: flex;\n align-items: center;\n padding: 0 34px;\n position: relative;\n}\n.her2-guide-section-title {\n font-size: 1.6em;\n font-weight: 600;\n color: #25507a;\n letter-spacing: 1px;\n margin: 0;\n padding: 18px 0;\n}\n.her2-guide-section-content {\n padding: 24px 34px 30px 34px;\n background: #ffffff;\n font-size: 1.18em;\n line-height: 2.1em;\n color: #24292f;\n}\n.her2-guide-section-content em {\n color: #437ad5;\n font-style: normal;\n}\n.her2-guide-section-content ul {\n margin: 12px 0 18px 24px;\n padding: 0 0 0 0;\n}\n.her2-guide-section-content ul > li {\n margin-bottom: 10px;\n font-size: 1em;\n list-style: disc inside;\n}\n.her2-guide-tip {\n margin: 16px 0 0 0;\n background: linear-gradient(90deg, #f7f8fd 40%, #f0f7fa 95%);\n border-left: 5px solid #69cfd4;\n border-radius: 7px;\n padding: 10px 22px;\n font-size: 1em;\n color: #256089;\n font-weight: 500;\n line-height: 1.8em;\n}\n.her2-guide-section-content b {\n color: #236cb9;\n font-weight: 600;\n}\n.her2-guide-section-content ol.her2-guide-reference-list {\n padding-left: 25px;\n font-size: 0.97em;\n line-height: 1.9em;\n}\n.her2-guide-reference-list i {\n color: #5370d7;\n}\n@media (max-width: 720px) {\n .her2-guide-container{\n padding: 12px 0 34px 0;\n max-width: 99%;\n border-radius: 12px;\n }\n .her2-guide-main-title {\n font-size: 1.6em;\n padding: 0 8px;\n }\n .her2-guide-section-content {\n padding: 16px 10px 18px 10px;\n font-size: 1em;\n }\n .her2-guide-section-bg {\n padding: 0 12px;\n min-height: 48px;\n }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"her2-guide-container\">\n \u003Ch2 id=\"material_title\" class=\"her2-guide-main-title\" style=\"co",518,"2025-07-23 10:16:40","HER2阳性乳腺癌, 靶向药物, 安全用药, 抗体药物偶联物, 小分子酪氨酸激酶抑制剂","本文深入解析HER2阳性乳腺癌靶向药物的分类、作用机制及使用注意事项，助力患者安全用药，确保疗效与健康。","2025-07-23 11:18:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]